Filtered By:
Condition: Disability
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 69960 results found since Jan 2013.
Botox For Migraine Headache Treatment
In conclusion, Botox is effective treatment for many headache patients with chronic, intractable migraines. Proper diagnosis and treatment must be given. For insurance to pay for Botox for migraine, specific criteria must be met. If you suffer from persistent, frequent headaches, call Sarasota Neurology today for an appointment. Start improving your quality of life today.
Source: Sarasota Neurology - November 11, 2014 Category: Neurologists Authors: Dan Kassicieh, D.O. Tags: Botox Migraines / Headache Pain Vertigo / Dizziness aspirin brain Cluster headaches depression Dr. Kassicieh memory Memory loss migraine treatment neurologist neurology Source Type: blogs
Aimovig Unique New Migraine Prevention
Migraine headaches are a chronic neurological disease condition. Migraines are not benign in that they are the number one leading cause of temporary total disability in the United States. Worldwide, migraines are reported as being one of the top 10 leading causes of disability. It is estimated that there are 38 million migraine sufferers in the United States and over 1 billion worldwide.
Migraine headaches are characterized by pain occurring on one side of the head or the other. The pain is moderate to severe in nature, generally limiting activities. Associated symptoms are light and sound sensitivity with some patients h...
Source: Sarasota Neurology - June 20, 2018 Category: Neurology Authors: admindan Tags: Migraines / Headache Uncategorized Aimovig CGRP headache specialist headaches migraine prevention receptor blocker Source Type: blogs
New Drug To Treat Migraines Shows Promise
(CNN) — A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options.
The drug, ubrogepant, showed greater rates of pain and symptom relief from migraine compared to a placebo, with more than 20% of participants given the drug reporting to be pain-free within two hours and more than 34% relieved of the most bothersome symptoms linked to migraine, which include light and noise sensitivity. This is compared to 14% and 27%, respectively, from the placebo.
“Having ubrogepant as a potential new medication for the acute treatment of m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Migraines Source Type: news
CGRP: A new era for migraine treatment
Migraine is a common medical condition, affecting as many as 37 million people in the US. It is considered a systemic illness, not just a headache. Recent research has demonstrated that changes may begin to occur in the brain as long as 24 hours before migraine symptoms begin. Many patients have a severe throbbing headache, often on only one side of the head. Some people are nauseated with vomiting. Many are light sensitive (photophobic) and sound sensitive (phonophobic), and these symptoms can persist after the pain goes away.
There are a variety of migraine subtypes with symptoms that include weakness, numbness, visual c...
Source: Harvard Health Blog - March 5, 2018 Category: Consumer Health News Authors: Carolyn A. Bernstein, MD, FAHS Tags: Drugs and Supplements Headache Health Migraines Pain Management Source Type: blogs
Improving access to care for patients with migraine in a remote Pacific population
Conclusion
Increased access to care provided benefits in reduction of specialist overutilization, reduction in hospitalizations, and reduction in disability. Patients with chronic migraine did not have increased use of medical resources or decreased productivity in this cohort.
Source: Neurology Clinical Practice - October 12, 2020 Category: Neurology Authors: Baker, V., Hack, N. Tags: Migraine, Cost effectiveness/economic, Access to care, Burden of disease, Training-international, Cross-cultural care Research Source Type: research
Chronic Pain – Stories Of Struggle And Hope: Part 4 – Migraines
BOSTON (CBS) – You may be dizzy. Nauseous. Light bothers you. Noise pierces you to the core. You’re not having a headache – you’re having a migraine.
Read-Listen: Chronic Pain – Stories Of Struggle And Hope: The Series
“When we speak of conditions like migraine most people think of it as a headache disorder. I always think of it as a headache plus disorder,” said Dr. Elizabeth Loder, Chief of the Division of Headache and Pain in the Neurology Department at Brigham and Women’s Hospital.
The Migraine Research Foundation says some 38 million Americans suffer from this syndrome. Health ca...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 12, 2016 Category: Consumer Health News Authors: miketoole Tags: Health Local News Syndicated Local Chronic Pain – Stories Of Struggle And Hope Migraines Rod Fritz Source Type: news
Total Migraine Freedom for Breath Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder (AVP-825) vs 100 mg Oral Sumatriptan from the COMPASS Study of Acute Treatment of Migraine (I3.009)
Conclusions: AVP-825 (22 mg sumatriptan) treatment of acute migraine results in higher rates of TMF at earlier timepoints than the most efficacious dose (100 mg) of oral-SUM, despite less drug exposure. These results demonstrate the superiority of AVP-825 using a more rigorous migraine efficacy endpoint. Findings are consistent with the other outcomes of COMPASS, indicating AVP-825 has superior early efficacy compared to oral-SUM. Supported by Avanir Pharmaceuticals, Inc.Disclosure: Dr. Halker has received personal compensation in an editorial capacity for Medlink; Current Neurology; Neuroscience Reports. Dr. Tepper has re...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Halker, R., Tepper, S., Shulman, K., Wallick, C. Tags: New and Emerging Therapeutic Options in Migraine and Other Headache Disorders Poster Presentations Source Type: research
Relivion Headset for Migraines Cleared in Europe
Neurolief, an Israeli company, has won European regulatory clearance (CE Mark) for its Relivion system to treat migraines.
Intended as an over-the-counter product, the non-invasive Relivion device delivers pulses of electric current into the p...
Source: Medgadget - July 12, 2019 Category: Medical Devices Authors: Medgadget Editors Tags: Medicine Neurology headache migraine noninvasive Source Type: blogs
Serotonin and Migraine Headaches
A serotonin migraine is due to a deficiency in a person's serotonin level. During a Serotonin migraine, the levels of Serotonin in a person's system may rise and suddenly fall prior to the migraine. Low levels of serotonin are linked to both migraines and depression.
Source: Disabled World - March 30, 2013 Category: Disability Tags: Migraines and Headaches Source Type: news
Effectiveness of Therapeutic Patient Education for Adults with Migraine. A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
ConclusionThis systematic review revealed strong‐moderate evidence for intermediate‐term effectiveness of therapeutic patient education for migraine. Further high‐quality RCTs are required for conclusive determination of its effectiveness.
Source: Pain Medicine - August 26, 2014 Category: Anesthesiology Authors: Paula Kindelan‐Calvo, Alfonso Gil‐Martínez, Alba Paris‐Alemany, Joaquín Pardo‐Montero, Daniel Muñoz‐García, Santiago Angulo‐Díaz‐Parreño, Roy La Touche Tags: Review Article Source Type: research
Suicide risk in patients with migraine and comorbid fibromyalgia
Conclusions:
Comorbidity with FM is associated with a high suicide risk in patients with migraine.
Source: Neurology - September 21, 2015 Category: Neurology Authors: Liu, H.-Y., Fuh, J.-L., Lin, Y.-Y., Chen, W.-T., Wang, S.-J. Tags: Migraine, All Pain, Depression, Risk factors in epidemiology ARTICLE Source Type: research
What's New in the Treatment of Migraine?
Conclusion:
Many new and exciting therapies exist for the treatment of migraine. Keeping up with this rapidly evolving field is important in reducing disability from the common disease of migraine.
Source: Journal of Neuro-Ophthalmology - August 30, 2019 Category: Opthalmology Tags: Disease of the Year: Migraine Source Type: research
Acute Care and Treatment of Migraine
Conclusion:
A wide variety of acute care options to treat migraine are available, and others will soon be and will herein be described in further detail. Some medications have been approved by regulatory authorities in countries other than the United States, and some devices have been given a CE Mark in Europe.
Source: Journal of Neuro-Ophthalmology - November 22, 2020 Category: Opthalmology Tags: Disease of the Year 2019 Encore: Migraine Source Type: research
Acupuncture prophylaxis of migraine no better than sham acupuncture for decreasing frequency of headaches
Commentary on: Li Y, Zheng H, Witt CM, et al. Acupuncture for migraine prophylaxis: a randomized controlled trial. Can Med AJ 2012;184:401–10. Context Migraine is a frequent and often disabling condition, in particular when migraine attacks occur frequently. Preventive therapy is recommended for patients with frequent attacks and related disability. Migraine prophylaxis can be performed with medications such as beta-blockers, flunarizine, amitriptyline and anti-epileptics such as valproic acid or topiramate.1 Non-drug treatment includes education, behavioural therapy and exercise. Acupuncture is popular in many Weste...
Source: Evidence-Based Medicine - January 17, 2013 Category: Internal Medicine Authors: Diener, H.-C. Tags: Clinical trials (epidemiology), Headache (including migraine), Pain (neurology), Drugs: psychiatry, Complementary medicine, Ethics Therapeutics Source Type: research
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study
Conclusions:
One-year efficacy, supported by functional improvements and favorable safety and tolerability profiles, supports further investigation of erenumab as a preventive treatment in patients with EM.
Clinicaltrials.gov identifier:
NCT01952574.
Classification of evidence:
This study provides Class IV evidence that for patients with episodic migraine, erenumab reduces long-term MMD and improves headache-related disability and migraine-specific quality of life.
Source: Neurology - September 18, 2017 Category: Neurology Authors: Ashina, M., Dodick, D., Goadsby, P. J., Reuter, U., Silberstein, S., Zhang, F., Gage, J. R., Cheng, S., Mikol, D. D., Lenz, R. A. Tags: Migraine, All Clinical trials, Class IV ARTICLE Source Type: research
